Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Mohler on Need for Genetic Counselors for Early Detection of Prostate Cancer

January 20th 2020

James L. Mohler, MD, discusses the need for genetic counselors in the detection and treatment of prostate cancer.

FDA Approvals Boost Competition in Treatment Landscapes

January 18th 2020

Therapeutic developments in cancer were rewarded with a wave of approvals in 2019.

Dr. Bryce on Next-Generation Radiopharmaceuticals in Prostate Cancer

January 17th 2020

Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the use of next-generation radiopharmaceuticals in prostate cancer.

FDA Grants Priority Review to Rucaparib for mCRPC

January 16th 2020

The FDA has granted a priority review designation to a supplemental new drug application for rucaparib for the treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castration-resistant prostate cancer.

Dr. Aoun on Imaging Modalities in Prostate Cancer

January 14th 2020

Hussein Aoun, MD, a radiologist at Barbara Ann Karmanos Cancer Institute, discusses the imaging modalities that are currently being used in prostate cancer and how they compare with conventional imaging modalities.

SITC Poised to Expand Toolkit of Immunotherapy Guidelines

January 11th 2020

The Society for Immunotherapy of Cancer is developing a growing menu of guidelines with treatment algorithms for specific cancer types to help practicing oncologists navigate the appropriate use of this emerging modality.

CARD Trial Establishes Cabazitaxel as a Third-Line Standard in mCRPC

January 9th 2020

Celestia S. Higano, MD, FACP, provides perspective on data from the CARD trial and their implications on clinical practice.

Dr. Chang on the Evolution of Surgical Techniques in Prostate Cancer

January 9th 2020

Sam S. Chang, MD, MBA, discusses the evolution of surgical techniques in prostate cancer.

Dr. Heath on Recent Approvals in Nonmetastic Prostate Cancer

January 9th 2020

Elisabeth I. Heath, MD, FACP, discusses apalutamide, enzalutamide, and darolutamide, which have all been approved for use in nonmetastatic castration-resistant prostate cancer.

Dr. Hwang on Choosing Agents for Prostate Cancer Treatment

January 8th 2020

Clara Hwang, MD, discusses factors that can be used to decide what agent to use in the frontline setting for patients with metastatic castration-sensitive or castration-resistant prostate cancer.

Novel Imaging Slated to Change Trajectory of Prostate Cancer Treatment

January 7th 2020

Hussein Aoun, MD, discusses the use of novel imaging modalities and contrasted them with conventional imaging tools in prostate cancer.

Antiandrogens Augment Growing Armamentarium in Metastatic Prostate Cancer

January 3rd 2020

Clara Hwang, MD, discusses key trials that have shaped the current treatment paradigms of metastatic castration-sensitive prostate cancer and metastatic castration-resistant prostate cancer.

Dr. Heath on the Toxicity Profiles of Oral Antiandrogens in Nonmetastatic CRPC

January 3rd 2020

Elisabeth I. Heath, MD, FACP, discusses the safety profiles of apalutamide, enzalutamide, and darolutamide in nonmetastatic castration-resistant prostate cancer.

Darolutamide Takes Root With New Prostate Cancer Benchmark

December 19th 2019

Matthew R. Smith, MD, PhD, discusses key facets of darolutamide (Nubeqa) therapy in the treatment of patients with nonmetastatic prostate cancer.

Novel AR-Directed Agents Transform Nonmetastatic CRPC Paradigm

December 18th 2019

Elisabeth I. Heath, MD, FACP, discusses 3 pivotal trials and how they have impacted clinical practice in nonmetastatic castration-resistant prostate cancer.

FDA Approves Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer

December 17th 2019

The FDA has approved a supplemental new drug application for enzalutamide (Xtandi) for the treatment of patients with metastatic castration-sensitive prostate cancer.

PARP Inhibitors Gain a Foothold in Prostate Cancer

December 12th 2019

Until strong findings emerged from the phase III PROfound study of PARP inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer, targeted therapy had an uncertain foothold in this tumor type.

Dr. Moses on Recent Trials in mHSPC

December 7th 2019

Kelvin Alexander Moses, MD, PhD, discusses recent trials in metastatic hormone-sensitive prostate cancer.

Dr. Oh on Remaining Challenges in mHSPC

December 7th 2019

William K. Oh, MD, discusses remaining challenges in metastatic hormone-sensitive prostate cancer.

Patient Factors Critical to Treatment Selection in Prostate Cancer, RCC

December 5th 2019

Kelvin Alexander Moses, MD, PhD, discusses relevant data and treatment decisions in metastatic hormone-sensitive prostate cancer, as well as the role of cytoreductive nephrectomy in RCC. 